Crit Care:血管渗漏指数可识别较高院内死亡风险的脓毒症患者

2022-04-16 MedSci原创 MedSci原创

VLI可识别高住院死亡或液体积聚风险的患者群体。这种关联在调整疾病严重程度和慢性合并疾病的模型中持续存在。

脓毒症是全球发病率和死亡率的主要原因。2017年,全球约有4900万例脓毒症病例,导致1100万相关死亡。脓毒症的医疗负担也很高,在美国,每年的医院费用超过240亿美元,成本也在不断上升。一项研究发现,在2015年至2018年的三年时间里,治疗医院脓毒症患者的相关费用增加了15亿美元。脓毒症的主要病理改变特点之一是血管渗漏。脓毒症的治疗,特别是静脉输液,可能会在血管渗漏的情况下恶化。

近日,危重病医学领域权威杂志Critical Care上发表了一篇研究文章,研究人员旨在寻求量化脓毒症患者的血管渗漏情况,以指导液体复苏治疗。

研究人员对北美、欧洲和亚洲的四个ICU数据库中的脓毒症患者进行了一项回顾性队列研究。此外,研究人员开发了一种直观的血管渗漏指数(VLI),并利用广义加性模型(GAM)探讨了VLI与住院死亡和体液平衡之间的关系。

研究人员使用GAM,发现VLI的增加与脓毒症患者住院死亡风险的增加有关。在四个数据集中,VLI最高四分位数(Q4)的患者与最低四分位数(Q1)的患者相比,住院死亡的几率增加了1.61-2.31倍。VLI的Q2和Q3也与死亡几率增加相关。VLI作为一个连续变量,与住院死亡和体液平衡之间的关系在三个大样本量的数据集中具有统计学意义。具体来说,研究人员观察到,随着VLI的增加,患者住院死亡和36-84小时体液平衡的风险增加。

由此可见,VLI可识别高住院死亡或液体积聚风险的患者群体。这种关联在调整疾病严重程度和慢性合并疾病的模型中持续存在。

原始出处:

Jay Chandra.et al.A novel Vascular Leak Index identifies sepsis patients with a higher risk for in-hospital death and fluid accumulation.Critical Care.2022.https://ccforum.biomedcentral.com/articles/10.1186/s13054-022-03968-4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1635257, encodeId=ac09163525eed, content=<a href='/topic/show?id=bb41983049e' target=_blank style='color:#2F92EE;'>#院内死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98304, encryptionId=bb41983049e, topicName=院内死亡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78f122436081, createdName=yuhaisheng_ibp_32061718, createdTime=Fri Oct 28 04:35:10 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211763, encodeId=54961211e63e8, content=这个研究很有意义!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=509f5553241, createdName=最后一支肾上腺素, createdTime=Sat Apr 16 23:03:53 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256195, encodeId=75d212561951c, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Apr 14 08:35:10 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516388, encodeId=222b151638877, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Thu Apr 14 08:35:10 CST 2022, time=2022-04-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1635257, encodeId=ac09163525eed, content=<a href='/topic/show?id=bb41983049e' target=_blank style='color:#2F92EE;'>#院内死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98304, encryptionId=bb41983049e, topicName=院内死亡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78f122436081, createdName=yuhaisheng_ibp_32061718, createdTime=Fri Oct 28 04:35:10 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211763, encodeId=54961211e63e8, content=这个研究很有意义!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=509f5553241, createdName=最后一支肾上腺素, createdTime=Sat Apr 16 23:03:53 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256195, encodeId=75d212561951c, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Apr 14 08:35:10 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516388, encodeId=222b151638877, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Thu Apr 14 08:35:10 CST 2022, time=2022-04-14, status=1, ipAttribution=)]
    2022-04-16 最后一支肾上腺素

    这个研究很有意义!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1635257, encodeId=ac09163525eed, content=<a href='/topic/show?id=bb41983049e' target=_blank style='color:#2F92EE;'>#院内死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98304, encryptionId=bb41983049e, topicName=院内死亡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78f122436081, createdName=yuhaisheng_ibp_32061718, createdTime=Fri Oct 28 04:35:10 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211763, encodeId=54961211e63e8, content=这个研究很有意义!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=509f5553241, createdName=最后一支肾上腺素, createdTime=Sat Apr 16 23:03:53 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256195, encodeId=75d212561951c, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Apr 14 08:35:10 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516388, encodeId=222b151638877, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Thu Apr 14 08:35:10 CST 2022, time=2022-04-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1635257, encodeId=ac09163525eed, content=<a href='/topic/show?id=bb41983049e' target=_blank style='color:#2F92EE;'>#院内死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98304, encryptionId=bb41983049e, topicName=院内死亡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78f122436081, createdName=yuhaisheng_ibp_32061718, createdTime=Fri Oct 28 04:35:10 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211763, encodeId=54961211e63e8, content=这个研究很有意义!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=509f5553241, createdName=最后一支肾上腺素, createdTime=Sat Apr 16 23:03:53 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256195, encodeId=75d212561951c, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Apr 14 08:35:10 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516388, encodeId=222b151638877, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Thu Apr 14 08:35:10 CST 2022, time=2022-04-14, status=1, ipAttribution=)]

相关资讯

Intensive Care Med:脓毒症异质性部分归因于感染源的差异

脓毒症异质性的部分原因是特异性宿主反应失调,感染源仍是宿主反应程度和特殊性的独立因素。

Crit Care:脓毒症成人延迟抗菌治疗和手术控制感染源的不良效应

该究的结果表明,抗菌治疗和感染源控制对于脓毒症治疗都至关重要。还没有感染性休克的患者可以从早期抗感染治疗中获益,因为它可以防止进一步恶化。

Crit Care:发热和体温过低是脓毒症患者的表现且与外界温度有关

脓毒症患者表现出体温过低或发热反应。低体温是否是一种适应不良反应,正如低温患者的死亡率较高所表明的那样,还是在较冷的环境条件下代谢储备有限的患者的适应性反应,仍然是一个悬而未决的问题。

Crit Care:蛋白C作为成人脓毒症的生物标志物

与非幸存者和脓毒症患者相比,脓毒症幸存者的蛋白C水平显著高于DIC患者。未来的研究需要确定蛋白C的敏感性和特异性,以确定其作为早期脓毒症识别生物标志物的临床意义。

硫胺素、维生素 C 和氢化可的松联合治疗脓毒症和感染性休克

最近的一项研究表明,2017年全球估计有1100万例败血症相关死亡,占总死亡人数的19.7%。在脓毒症患者中经常检测到维生素C和硫胺素的缺乏,据报道,这归因于摄入量减少和代谢需求增加。

烧伤后脓毒症的发病机制及诊断

。脓毒症是烧伤最常见的并发症之一,是烧伤患者死亡的主要原因。